US pharmaceutical company Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics Inc, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, announced on Tuesday a definitive agreement for Lilly to acquire SiteOne.
The deal includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain.
"Lilly is eager to continue the development of STC-004 with the outstanding SiteOne team as part of our efforts to advance novel, addiction-free pain therapies," said Mark Mintun, Lilly group vice president Neuroscience Research and Development.
Under the terms of the agreement Lilly will acquire SiteOne, and SiteOne shareholders could receive up to USD1.0bn in cash, including an upfront payment and subsequent payments upon achievement of certain regulatory and commercial milestones.
The transaction is subject to customary closing conditions.
Clarity Pharmaceuticals images first patient in 64Cu-SAR-bisPSMA PET/CT Phase III AMPLIFY trial
Astellas agrees XNW27011 licensing deal with Evopoint Biosciences
Genentech reports sustained two-year benefits from fenebrutinib in relapsing multiple sclerosis
Drug Farm reports positive Phase 1 trial results for DF-003 in healthy volunteers
Estrella Immunopharma initiates second cohort in EB103 trial for advanced B-cell lymphomas
Innovent commences Phase 3 study of picankibart in psoriasis patients
Kexing Biopharm's IND application for GB18 approved by US and Chinese regulators
Apotex launches generic version of Tasigna in US market
Lilly acquires SiteOne Therapeutics to expand pain pipeline
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
CARsgen's Satri-cel granted Chinese Priority Review
RemeGen secures approval in China for Telitacicept in treating generalised myasthenia gravis